Prostanoid Therapy for Pulmonary Arterial Hypertension

Rubin, 1982, Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension, Circulation, 66, 334, 10.1161/01.CIR.66.2.334 Higenbottam, 1984, Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin), Lancet, 1, 1046, 10.1016/S0140-6736(84)91452-1 Barst, 1996, A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group, N Engl J Med, 334, 296, 10.1056/NEJM199602013340504 Melian, 2002, Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension, Drugs, 62, 107, 10.2165/00003495-200262010-00005 Wishart, 2006, Drugbank: a comprehensive resource for in silico drug discovery and exploration, Nucleic Acids Res, 34, D668, 10.1093/nar/gkj067 Humbert, 2004, Cellular and molecular pathobiology of pulmonary arterial hypertension, J Am Coll Cardiol, 43, 13S, 10.1016/j.jacc.2004.02.029 Jeffery, 2002, Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension, Prog Cardiovasc Dis, 45, 173, 10.1053/pcad.2002.130041 Mandegar, 2004, Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension, Microvasc Res, 68, 75, 10.1016/j.mvr.2004.06.001 Moncada, 1976, An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation, Nature, 263, 663, 10.1038/263663a0 Ubatuba, 1979, The effect of prostacyclin (PGT2) on platelet behaviour. Thrombus formation in vivo and bleeding time, Thromb Haemost, 41, 425, 10.1055/s-0038-1646791 Szczeklik, 1978, Circulatory and anti-platelet effects of intravenous prostacyclin in healthy men, Pharmacol Res Commun, 10, 545, 10.1016/S0031-6989(78)80053-8 Whittle, 1980, Role of prostaglandins in the defense of the gastric mucosa, Brain Res Bull, 5, 7, 10.1016/0361-9230(80)90297-X Ogletree, 1979, Studies on the protective effect of prostacyclin in acute myocardial ischemia, Eur J Pharmacol, 56, 95, 10.1016/0014-2999(79)90438-2 Ribeiro, 1981, Prostacyclin in experimental myocardial ischemia: effects on hemodynamics, regional myocardial blood flow, infarct size and mortality, Am J Cardiol, 47, 835, 10.1016/0002-9149(81)90182-X Demling, 1981, The effect of prostacyclin infusion on endotoxin-induced lung injury, Surgery, 89, 257 McLaughlin, 1998, Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension, N Engl J Med, 338, 273, 10.1056/NEJM199801293380501 Friedman, 1997, Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension, Circulation, 96, 2782, 10.1161/01.CIR.96.9.2782 Sakamaki, 2000, Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertension were improved by continuous prostacyclin therapy, Circulation, 102, 2720, 10.1161/01.CIR.102.22.2720 Langleben, 1999, Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension, Circulation, 99, 3266, 10.1161/01.CIR.99.25.3266 Giaid, 1993, Expression of endothelin-1 in the lungs of patients with pulmonary hypertension, N Engl J Med, 328, 1732, 10.1056/NEJM199306173282402 Sulica, 2005, The acute hemodynamic effect of IV nitroglycerin and dipyridamole in patients with pulmonary arterial hypertension: comparison with IV epoprostenol, Congest Heart Fail, 11, 139, 10.1111/j.1527-5299.2005.03885.x Montalescot, 1998, Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end-stage heart failure, Am J Cardiol, 82, 749, 10.1016/S0002-9149(98)00439-1 Tuder, 1999, Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension, Am J Respir Crit Care Med, 159, 1925, 10.1164/ajrccm.159.6.9804054 Christman, 1992, An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension, N Engl J Med, 327, 70, 10.1056/NEJM199207093270202 Tahara, 2004, Repeated gene transfer of naked prostacyclin synthase plasmid into skeletal muscles attenuates monocrotaline-induced pulmonary hypertension and prolongs survival in rats, Hum Gene Ther, 15, 1270, 10.1089/hum.2004.15.1270 Geraci, 1999, Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension, J Clin Invest, 103, 1509, 10.1172/JCI5911 Hoshikawa, 2001, Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling, Am J Respir Crit Care Med, 164, 314, 10.1164/ajrccm.164.2.2010150 Wharton, 2000, Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells, Circulation, 102, 3130, 10.1161/01.CIR.102.25.3130 Clapp, 2002, Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery, Am J Respir Cell Mol Biol, 26, 194, 10.1165/ajrcmb.26.2.4695 Kothapalli, 2003, Prostacylin receptor activation inhibits proliferation of aortic smooth muscle cells by regulating cAMP response element-binding protein- and pocket protein-dependent cyclin a gene expression, Mol Pharmacol, 64, 249, 10.1124/mol.64.2.249 Li, 2004, Prostacyclin induces apoptosis of vascular smooth muscle cells by a cAMP-mediated inhibition of extracellular signal-regulated kinase activity and can counteract the mitogenic activity of endothelin-1 or basic fibroblast growth factor, Circ Res, 94, 759, 10.1161/01.RES.0000121568.40692.97 Vane, 1995, Pharmacodynamic profile of prostacyclin, Am J Cardiol, 75, 3A, 10.1016/S0002-9149(99)80377-4 Califf, 1997, A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST), Am Heart J, 134, 44, 10.1016/S0002-8703(97)70105-4 Long, 1987, Prostacyclin and PGE1 treatment of pulmonary hypertension, Am Rev Respir Dis, 136, 773, 10.1164/ajrccm/136.3.773 Jones, 1987, Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin), Br Heart J, 57, 270, 10.1136/hrt.57.3.270 Rubin, 1990, Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial, Ann Intern Med, 112, 485, 10.7326/0003-4819-112-7-485 Barst, 1994, Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin, Ann Intern Med, 121, 409, 10.7326/0003-4819-121-6-199409150-00003 D'Alonzo, 1991, Survival in patients with primary pulmonary hypertension. Results from a national prospective registry, Ann Intern Med, 115, 343, 10.7326/0003-4819-115-5-343 Badesch, 2000, Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial, Ann Intern Med, 132, 425, 10.7326/0003-4819-132-6-200003210-00002 McLaughlin, 2002, Survival in primary pulmonary hypertension: the impact of epoprostenol therapy, Circulation, 106, 1477, 10.1161/01.CIR.0000029100.82385.58 Sitbon, 2002, Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival, J Am Coll Cardiol, 40, 780, 10.1016/S0735-1097(02)02012-0 Conte, 1998, The influence of continuous intravenous prostacyclin therapy for primary pulmonary hypertension on the timing and outcome of transplantation, J Heart Lung Transplant, 17, 679 Edelman, 2000, Has prostacyclin replaced transplantation as the treatment of choice for primary pulmonary hypertension, Clinical Pulmonary Medicine, 7, 90, 10.1097/00045413-200007020-00005 Flolan (epoprostenol sodium) for Injection [package insert]. Research Triangle Park (NC): GlaxoSmithKline; 2006. Galie, 2004, Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the European society of cardiology, Eur Heart J, 25, 2243, 10.1016/j.ehj.2004.09.014 Wasserman, 2000, Overdosing with prostacyclin in primary pulmonary hypertension, J Am Coll Cardiol, 35, 1995, 10.1016/S0735-1097(00)00662-8 Remodulin (treprostinil sodium) Injection [package insert]. Research Triangle Park (NC): Corp UT; 2006. Simonneau, 2002, Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial, Am J Respir Crit Care Med, 165, 800, 10.1164/ajrccm.165.6.2106079 Lang, 2006, Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension, Chest, 129, 1636, 10.1378/chest.129.6.1636 Barst, 2006, Long-term outcome in pulmonary arterial hypertension patients treated with treprostinil, Eur Respir J, 28, 1195, 10.1183/09031936.06.00044406 Laliberte, 2004, Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers, J Cardiovasc Pharmacol, 44, 209, 10.1097/00005344-200408000-00010 McLaughlin, 2003, Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension, J Cardiovasc Pharmacol, 41, 293, 10.1097/00005344-200302000-00019 Tapson, 2006, Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial, Chest, 129, 683, 10.1378/chest.129.3.683 Gomberg-Maitland, 2005, Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension, Am J Respir Crit Care Med, 172, 1586, 10.1164/rccm.200505-766OC Sandifer, 2005, Potent effects of aerosol compared with intravenous treprostinil on the pulmonary circulation, J Appl Physiol, 99, 2363, 10.1152/japplphysiol.00083.2005 Sandifer, 2005, Effects of aerosol vs IV UT-15 on prostaglandin H2 analog-induced pulmonary hypertension in sheep, Chest, 128, 616S, 10.1378/chest.128.6_suppl.616S Voswinckel, 2006, Inhaled treprostinil [corrected] for treatment of chronic pulmonary arterial hypertension, Ann Intern Med, 144, 149, 10.7326/0003-4819-144-2-200601170-00026 Channick, 2006, Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension, J Am Coll Cardiol, 48, 1433, 10.1016/j.jacc.2006.05.070 Higenbottam, 1998, Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost, Heart, 79, 175, 10.1136/hrt.79.2.175 Scott, 1990, The acute effect of the synthetic prostacyclin analogue iloprost in primary pulmonary hypertension, Br J Clin Pract, 44, 231, 10.1111/j.1742-1241.1990.tb10799.x Gessler, 2001, Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension, Eur Respir J, 17, 14, 10.1183/09031936.01.17100140 Ventavis (iloprost) Inhalation Solution [package insert]. South San Francisco (CA): Cotherix; 2006. Hoeper, 2000, Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue, N Engl J Med, 342, 1866, 10.1056/NEJM200006223422503 Olschewski, 2002, Inhaled iloprost for severe pulmonary hypertension, N Engl J Med, 347, 322, 10.1056/NEJMoa020204 Opitz, 2005, Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension, Eur Heart J, 26, 1895, 10.1093/eurheartj/ehi283 Seyfarth, 2005, Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy, Chest, 128, 709, 10.1378/chest.128.2.709 Hoeper, 2003, Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids, Eur Respir J, 22, 330, 10.1183/09031936.03.00008003 Ghofrani, 2003, Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension, J Am Coll Cardiol, 42, 158, 10.1016/S0735-1097(03)00555-2 Okano, 1997, Orally active prostacyclin analogue in primary pulmonary hypertension, Lancet, 349, 1365, 10.1016/S0140-6736(97)24019-5 Nagaya, 1999, Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension, J Am Coll Cardiol, 34, 1188, 10.1016/S0735-1097(99)00312-5 Galie, 2002, Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial, J Am Coll Cardiol, 39, 1496, 10.1016/S0735-1097(02)01786-2 Barst, 2003, Beraprost therapy for pulmonary arterial hypertension, J Am Coll Cardiol, 41, 2119, 10.1016/S0735-1097(03)00463-7 McLaughlin, 2006, Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension, Am J Respir Crit Care Med, 174, 1257, 10.1164/rccm.200603-358OC Humbert, 2004, Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2, Eur Respir J, 24, 353, 10.1183/09031936.04.00028404 Rich, 1987, Primary pulmonary hypertension. A national prospective study, Ann Intern Med, 107, 216, 10.7326/0003-4819-107-2-216 Barst, 1999, Vasodilator therapy for primary pulmonary hypertension in children, Circulation, 99, 1197, 10.1161/01.CIR.99.9.1197 Rosenzweig, 1999, Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects, Circulation, 99, 1858, 10.1161/01.CIR.99.14.1858 Wigley, 2005, The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study), Arthritis Rheum, 52, 2125, 10.1002/art.21131 Oudiz, 2004, Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease, Chest, 126, 420, 10.1378/chest.126.2.420 Matsukawa, 2002, Long-term administration of beraprost, an oral prostacyclin analogue, improves pulmonary diffusion capacity in patients with systemic sclerosis, Prostaglandins Leukot Essent Fatty Acids, 67, 45, 10.1054/plef.2002.0380 Caramaschi, 2005, Long-term evaluation of lung function in patients affected by scleroderma treated with cyclic iloprost infusions, Rheumatol Int, 25, 250, 10.1007/s00296-004-0439-z Ghofrani, 2004, Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension, Eur Respir J, 23, 321, 10.1183/09031936.03.00057703 Aguilar, 2000, Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension, Am J Respir Crit Care Med, 162, 1846, 10.1164/ajrccm.162.5.2004042 Nunes, 2003, Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension, Am J Respir Crit Care Med, 167, 1433, 10.1164/rccm.200204-330OC Kuo, 1997, Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension, Transplantation, 63, 604, 10.1097/00007890-199702270-00020 Krowka, 1999, Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension, Hepatology, 30, 641, 10.1002/hep.510300307 Plotkin, 1998, Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension, Transplantation, 65, 457, 10.1097/00007890-199802270-00001 Kahler, 2000, Successful use of continuous intravenous prostacyclin in a patient with severe portopulmonary hypertension, Wien Klin Wochenschr, 112, 637 Tan, 2001, Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol, Liver Transpl, 7, 745, 10.1053/jlts.2001.26057 Minder, 2004, Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension, Eur Respir J, 24, 703, 10.1183/09031936.04.00133203 Halank, 2005, Combination therapy for portopulmonary hypertension with intravenous iloprost and oral bosentan, Wien Med Wochenschr, 155, 376, 10.1007/s10354-005-0196-y Laving, 2005, Successful liver transplantation in a child with severe portopulmonary hypertension treated with epoprostenol, J Pediatr Gastroenterol Nutr, 41, 466, 10.1097/01.mpg.0000178441.10417.0f Sussman, 2006, Successful liver transplantation following medical management of portopulmonary hypertension: a single-center series, Am J Transplant, 6, 2177, 10.1111/j.1600-6143.2006.01432.x Chinnakotla, 2006, Liver transplantation in patients with severe portopulmonary hypertension, Transplantation, 82, 331 Fix, 2006, Long-term follow-up of portopulmonary hypertension treated with epoprostenol, Transplantation, 82, 331 Ono, 2003, Effect of orally active prostacyclin analogue on survival in patients with chronic thromboembolic pulmonary hypertension without major vessel obstruction, Chest, 123, 1583, 10.1378/chest.123.5.1583 Ghofrani, 2002, Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension, Ann Intern Med, 136, 515, 10.7326/0003-4819-136-7-200204020-00008 Vizza CD, Badagliacca R, Sciomer S, Poscia R, et al. Mid-term efficacy of beraprost, an oral prostacyclin analog, in the treatment of distal CTEPH: a case control study. Cardiology. 2006;106(3):168–73. Walmrath, 1996, Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome, Am J Respir Crit Care Med, 153, 991, 10.1164/ajrccm.153.3.8630585 Dahlem, 2004, Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury, Crit Care Med, 32, 1055, 10.1097/01.CCM.0000120055.52377.BF Fattouch, 2006, Treatment of pulmonary hypertension in patients undergoing cardiac surgery with cardiopulmonary bypass: a randomized, prospective, double-blind study, J Cardiovasc Med (Hagerstown), 7, 119, 10.2459/01.JCM.0000203850.97890.fe De Wet, 2004, Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery, J Thorac Cardiovasc Surg, 127, 1058, 10.1016/j.jtcvs.2003.11.035 Kramm, 2005, Inhaled iloprost to control residual pulmonary hypertension following pulmonary endarterectomy, Eur J Cardiothorac Surg, 28, 882, 10.1016/j.ejcts.2005.09.007 Ocal, 2005, Efficiency of prostacyclin in the treatment of protamine-mediated right ventricular failure and acute pulmonary hypertension, Tohoku J Exp Med, 207, 51, 10.1620/tjem.207.51